In this week’s blog, we’d like to introduce you to Personalized Stem Cells’ Chief Business Officer, Stephen Keane. Mr. Keane joined the Personalized Stem Cells team in early 2022. He had previously collaborated with PSC and has known PSC CEO, Dr. Bob Harman, for many years. He is a seasoned life sciences executive and brings many years of experience in the biopharmaceutical and biotechnology fields.

Mr. Keane has an extensive track record of success in corporate development, business development, and financial transactions for emerging biopharmaceutical companies. He has been an officer of four publicly traded biotechnology companies, raised over $450 million in equity capital in the last two decades, and has helped generate more than $425 million in non-dilutive partner revenues to fund drug discovery programs.

Mr. Keane co-founded several companies including Staurus Pharma, Pacific Integrated Manufacturing, and Iogen Inc. He has served as Chief Business Officer of Calidi Biotherapeutics, Senior Vice President of Leading Biosciences, and President and CEO of Femta Pharmaceuticals. He has also held senior corporate development positions with Ambit Biosciences, Cosmo Pharmaceuticals, Dendreon Corp., Corvas International, Epimmune Inc., SIBIA Neurosciences, and Molecular Biosystems. He was responsible for negotiating significant alliances including licenses, distributions agreements, technology acquisitions, and research agreements with large pharmaceutical companies and government agencies. He also served as the principal negotiator for Dendreon’s acquisition of Corvas International and Merck’s acquisition of SIBIA Neurosciences.

PSC is fortunate to have such an experienced executive as an integral part of the team. We look forward to tapping into his vast knowledge base to help grow PSC’s offerings in the coming months.